dc.contributor.author | Annibaldi, A | |
dc.contributor.author | Meier, P | |
dc.date.accessioned | 2017-12-22T10:09:58Z | |
dc.date.issued | 2018-01-01 | |
dc.identifier.citation | Trends in molecular medicine, 2018, 24 (1), pp. 49 - 65 | |
dc.identifier.issn | 1471-4914 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/986 | |
dc.identifier.eissn | 1471-499X | |
dc.identifier.doi | 10.1016/j.molmed.2017.11.002 | |
dc.description.abstract | Tumor necrosis factor (TNF) is a proinflammatory cytokine that coordinates tissue homeostasis by regulating cytokine production, cell survival, and cell death. However, how life and death decisions are made in response to TNF is poorly understood. Many inflammatory pathologies are now recognized to be driven by aberrant TNF-induced cell death, which, in most circumstances, depends on the kinase Receptor-interacting serine/threonine-protein kinase 1 (RIPK1). Recent advances have identified ubiquitin (Ub)-mediated phosphorylation of RIPK1 as belonging to crucial checkpoints for cell fate in inflammation and infection. A better understanding of these checkpoints might lead to new approaches for the treatment of chronic inflammatory diseases fueled by aberrant RIPK1-induced cell death, and/or reveal novel strategies for anticancer immunotherapies, harnessing the ability of RIPK1 to trigger immunogenic cell death. | |
dc.format | Print-Electronic | |
dc.format.extent | 49 - 65 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCI LTD | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.subject | Animals | |
dc.subject | Humans | |
dc.subject | Neoplasms | |
dc.subject | Inflammation | |
dc.subject | Tumor Necrosis Factor-alpha | |
dc.subject | NF-kappa B | |
dc.subject | Ubiquitin | |
dc.subject | Cell Death | |
dc.subject | Receptor-Interacting Protein Serine-Threonine Kinases | |
dc.title | Checkpoints in TNF-Induced Cell Death: Implications in Inflammation and Cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-11-13 | |
rioxxterms.versionofrecord | 10.1016/j.molmed.2017.11.002 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2018-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Trends in molecular medicine | |
pubs.issue | 1 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Cell Death and Immunity | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Cell Death and Immunity | |
pubs.publication-status | Published | |
pubs.volume | 24 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Cell Death and Immunity | |
dc.contributor.icrauthor | Meier, Pascal | |